CCT6A and pulmonary fibrosis: As a result, mice overexpressing Cct6a showed significant attenuation of BLM-induced pulmonary fibrosis, including decreased lactate levels in serum and decreased lipid accumulation in the lungs, further demonstrating the therapeutic potential of CCT6A as a possible clinical target.